Evidence map›Paper›PMID 34191241›Full record

ArticleEuropean journal of hybrid imaging2020

Tessel M Boertien, Jan Booij, Charles B L M Majoie, Madeleine L Drent, Alberto M Pereira, Nienke R Biermasz, Suat Simsek, Ronald Groote Veldman, Marcel P M Stokkel, Peter H Bisschop and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of hybrid imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Functional pituitary adenoma imaging.Reviews in endocrine & metabolic disorders · 2026
    Review
  2. Molecular Brain Tumor Imaging Beyond [AJR. American journal of roentgenology · 2026
    Review
  3. Article
  4. Somatostatin Receptor-PET/CT/MRI of Head and Neck Neuroendocrine Tumors.AJNR. American journal of neuroradiology · 2023
    Article
  5. Aggressive pituitary tumours and pituitary carcinomas.Nature reviews. Endocrinology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Tessel M BoertienDepartment of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands. t.m.boertien@amsterdamumc.nl.ORCID http://orcid.org/0000-0002-1285-4834
Jan BooijDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.
Charles B L M MajoieDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.
Madeleine L DrentDepartment of Internal Medicine, Section of Endocrinology, Amsterdam UMC, VU University, De Boelelaan 1117, Amsterdam, the Netherlands.
Alberto M PereiraDepartment of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden (CETL), Leiden University Medical Center, Leiden, the Netherlands.
Nienke R BiermaszDepartment of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden (CETL), Leiden University Medical Center, Leiden, the Netherlands.
Suat SimsekDepartment of Internal Medicine, Section of Endocrinology, Amsterdam UMC, VU University, De Boelelaan 1117, Amsterdam, the Netherlands.
Ronald Groote VeldmanDepartment of Internal Medicine, Medical Spectrum Twente, Enschede, the Netherlands.
Marcel P M StokkelDepartment of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Peter H Bisschop *Department of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.
Eric Fliers *Department of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.
Amsterdam University Medical Centers · NLLeiden University Medical Center · NLMedisch Spectrum Twente · NLNorthwest Hospital · USThe Netherlands Cancer Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeClinically non-functioning pituitary macroadenomas (NFMA) have been reported to express somatostatin receptors (SSTR), but results are inconsistent across different studies. This may be related to limited sensitivity and specificity of techniques used to date, i.e. immunohistochemistry in surgical specimens and

methodsThirty-seven patients diagnosed with NFMA underwent

results

conclusionsThis is the first report of

trial registrationNetherlands Trial Register, NL5136, registered on 18 August 2015; EudraCT, 2015-001234-22, registered on 10 March 2015, https://eudract.ema.europa.eu/.

Indexed as

68Ga-DOTATATEMRI co-registrationNon-functioning pituitary adenomaPET/CTSomatostatin receptors

Identifiers

PMID34191241
PMCPMC8218160
OpenAlexW3031527245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.